The Reduced Release of GH by GHRH in 8 Subjects Aged 65–69 Years Is Augmented Considerably by Rivastigmine, a Drug for Alzheimer’s Disease

Publisher： Karger

E-ISSN： 1423-0003|49|3|191-195

ISSN： 0304-324x

Source： Gerontology, Vol.49, Iss.3, 2003-04, pp. : 191-195

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Effects of rivastigmine on common symptomatology of Alzheimer’s disease (EXPLORE)

By Gauthier Serge   Juby Angela   Dalziel William   Réhel Bonita   Schecter Robyn  

Current Medical Research and Opinion, Vol. 26, Iss. 5, 2010-05 ,pp. : 1149-1160

Informa Healthcare

Access to resources Recommend Favorite

Pain and Alzheimer’s Disease

By  

Gerontology, Vol. 46, Iss. 5, 2000-08 ,pp. : 235-241

Karger

Access to resources Recommend Favorite

Somatotype in Alzheimer’s Disease

By  

Gerontology, Vol. 53, Iss. 4, 2007-03 ,pp. : 200-204

Karger

Access to resources Recommend Favorite

A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer’s disease: a post hoc analysis

By Farlow Martin R.   Alva Gus   Meng Xiangyi   Olin Jason T.  

Current Medical Research and Opinion, Vol. 26, Iss. 2, 2010-02 ,pp. : 263-269

Informa Healthcare

Access to resources Recommend Favorite

Normal and Pathological Aging of Attention in Presymptomatic Huntington’s, Huntington’s and Alzheimer’s Disease, and Nondemented Elderly Subjects

By  

Psychotherapy and Psychosomatics, Vol. 77, Iss. 3, 2008-02 ,pp. : 139-146

Karger

Access to resources Recommend Favorite